(Q80092106)

English

FDA drug approval summary: bevacizumab plus FOLFOX4 as second-line treatment of colorectal cancer

scientific article published on 01 March 2007

Statements

FDA drug approval summary: bevacizumab plus FOLFOX4 as second-line treatment of colorectal cancer (English)

Identifiers

 
edit
    edit
      edit
        edit
          edit
            edit
              edit
                edit
                  edit